3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 24 points (-0.1%) at 18,483 as of Friday, July 15, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,378 issues advancing vs. 1,527 declining with 156 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

Teva Pharmaceutical Industries

(

TEVA

), down 1.7%,

Shire

(

SHPG

), down 1.0%,

Sanofi

(

SNY

), down 0.8%,

Eli Lilly and

(

LLY

), down 0.7% and

Pfizer

(

PFE

), down 0.5%. Top gainers within the industry include

Vertex Pharmaceuticals

(

VRTX

), up 2.4%,

Incyte

(

INCY

), up 2.2%,

Regeneron Pharmaceuticals

(

REGN

), up 1.9% and

Celgene

(

CELG

), up 1.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Novartis

(

NVS

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.52 (-0.6%) to $81.50 on average volume. Thus far, 853,194 shares of Novartis exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $81.46-$82.00 after having opened the day at $81.76 as compared to the previous trading day's close of $82.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. Novartis has a market cap of $195.3 billion and is part of the health care sector. Shares are down 4.7% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Novartis a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Novartis

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Bristol-Myers Squibb Company

(

BMY

) is down $0.98 (-1.3%) to $75.78 on average volume. Thus far, 4.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 6.0 million shares. The stock has ranged in price between $75.76-$77.12 after having opened the day at $77.11 as compared to the previous trading day's close of $76.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $127.8 billion and is part of the health care sector. Shares are up 11.6% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Bristol-Myers Squibb Company Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is down $0.36 (-0.6%) to $59.29 on average volume. Thus far, 3.5 million shares of Merck exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $59.25-$59.93 after having opened the day at $59.80 as compared to the previous trading day's close of $59.65.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $164.8 billion and is part of the health care sector. Shares are up 12.9% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...